Vistusertib
- Generic Name
- Vistusertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30N6O3
- CAS Number
- 1009298-59-2
- Unique Ingredient Identifier
- 0BSC3P4H5X
- Background
Vistusertib is under investigation for the treatment of Advanced Gastric Adenocarcinoma.
- Associated Conditions
- -
- Associated Therapies
- -
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
Phase 1
Terminated
- Conditions
- Metastatic Malignant Solid NeoplasmRecurrent Lung Small Cell CarcinomaRecurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmStage IIIA Lung Small Cell Carcinoma AJCC v7Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7Stage IIIB Lung Small Cell Carcinoma AJCC v7Stage IV Lung Small Cell Carcinoma AJCC v7Unresectable Solid Neoplasm
- Interventions
- Biological: NavitoclaxDrug: Vistusertib
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT03366103
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath